Cyclic Peptide Regulating Plexin Binding Interface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The interaction between Semaphorin and Plexin presents a wide and flat bonding surface, making it challenging for conventional low-molecular drugs to effectively target and regulate Plexin, which is crucial for therapies related to cancer, bone metabolism, and neurodegenerative diseases.
Innovation Solution
A cyclic peptide with specific structures such as Arg-Trp-Thr, Leu-Ser-Trp, or Val/Ile-Xaa1-Arg-Trp-Thr, which binds to Plexin to allosterically regulate signal transmission between Semaphorin and Plexin, particularly targeting Plexin A1 and B1, thereby modulating their interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If conventional low-molecular drugs are used to target Plexin, then the drug size is small and easy to administer, but the drugs cannot effectively bind to the wide and flat bonding surface of Plexin
Solution Approach 1:
The patent changes the molecular size parameter from small (conventional drugs) to large (cyclic peptide), enabling the drug to effectively cover and bind to the wide and flat bonding surface of Plexin. The cyclic peptide's extended structure allows it to span the large interaction interface that small molecules cannot cover.
2Reliability
If a large molecule like cyclic peptide is used to target Plexin, then the binding effectiveness improves, but the drug complexity and manufacturing difficulty increase
Solution Approach 1:
The cyclic peptide is designed with a specific segmented structure containing key amino acid sequences (Arg-Trp-Thr or Leu-Ser-Trp) that are critical for Plexin binding. This segmentation allows the large molecule to have organized functional regions that enhance binding effectiveness while providing a systematic approach to managing molecular complexity.
Solution Approach 2:
The patent employs a cyclic (ring-shaped) peptide structure rather than a linear chain. This cyclic configuration provides structural stability and rigidity, reducing the complexity of conformational dynamics while maintaining the ability to engage the flat bonding surface of Plexin effectively.
3Ease of operation
If conventional drugs are used, then the treatment approach is simple, but they cannot effectively regulate the Semaphorin-Plexin interaction
Solution Approach 1:
The cyclic peptide acts as an intermediary molecule that specifically binds to Plexin and modulates the Semaphorin-Plexin interaction. This mediator approach allows for effective regulation of the protein-protein interaction that conventional drugs cannot achieve, while the peptide's specific structure enables targeted intervention in the signaling pathway.
Data Source
AI summary
The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.